Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-364 in Advanced Solid Tumors
NCT07847905Phase 2Not yet recruiting
- Sponsor
- LaNova Medicines
- Start
- Oct 2026
- Primary completion
- Oct 2030
- Countries
- 1
01
Overview
Phase 2, open-label trial of LM-364 in solid tumor (advanced stage) (2 arms), sponsored by LaNova Medicines. Primary endpoints: Dose Limiting Toxicity at 78 weeks, Adverse Events at 78 weeks and 2 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
LM-364
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07847905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07847905.